Diligence memo · auto-generated · as of July 2, 2026

Soleno Therapeutics Inc

Soleno Therapeutics Inc looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Soleno Therapeutics Inc operates in Pharma, based in REDWOOD CITY.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Soleno Therapeutics Inc has raised $99M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).

Largest single filing: $60M on 2023-10-02.

Most recent recorded round closed around 2023-10-02.

Valuation (modeled)modeled

Provath models Soleno Therapeutics Inc at approximately $681M (range $195M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.07× the median modeled value of Series C Pharma companies in 2022–2024 (7 peers) — value vs value, same stage and era. Within the normal band (107% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 15 months.

Last raise 2.7 yr ago; this sector typically re-raises about every 16 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 4.0× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 90% of Pharma peers (310 compared).

Modeled value ranks above 88% of those peers.

Closest niche peers: Circle Pharma, Inc., Averna Therapeutics Inc., Progentos Therapeutics, Inc., Intrinsic Therapeutics Inc, Digital Therapeutics, Inc..

Peoplefiled

24 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.